MedTrace Logo

Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

NCT07038941 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-06-26

No results posted yet for this study

Summary

This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out:

1. Whether single and repeated daily doses of CG2001 are safe and well-tolerated
2. How much of the drug, if any, enters the bloodstream (pharmacokinetics)

Conditions

  • Male Pattern of Hair Loss, Androgenic Alopecia
  • Androgenetic Alopecia (AGA)

Interventions

DRUG

CG2001

combination of minoxidil and finasteride

DRUG

Placebo foam

Placebo foam

Sponsors & Collaborators

  • Beijing Dayspring Pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yi Fang, MD, PhD · Peking University People's Hospital

  • Jianzhong Zhang, MD, PhD · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-19
Primary Completion
2024-06-02
Completion
2024-06-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07038941 on ClinicalTrials.gov